Omeprazole
- Generic Name
- Omeprazole
- Brand Names
- Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 73590-58-6
- Unique Ingredient Identifier
- KG60484QX9
- Background
Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approva...
- Indication
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
...
- Associated Conditions
- Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
- Associated Therapies
- -
Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)
- Conditions
- Interventions
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT02647086
- Locations
- 🇺🇸
Regeneron Study Site, Raleigh, North Carolina, United States
A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT02638116
A Two Week Nitazoxanidebased Quadruple Regimen
- Conditions
- Interventions
- First Posted Date
- 2015-12-03
- Last Posted Date
- 2018-01-03
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 100
- Registration Number
- NCT02621359
- Locations
- 🇪🇬
Tropical medicine dept.-Tanta university hospital, Tanta, Egypt
IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Brooklyn ImmunoTherapeutics, LLC
- Target Recruit Count
- 105
- Registration Number
- NCT02609386
- Locations
- 🇬🇧
Queen Elizabeth University Hospital Glasgow, Glasgow, United Kingdom
🇺🇸Monter Cancer Center - North Shore LIJ, New Hyde Park, New York, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Kathy Miller
- Target Recruit Count
- 42
- Registration Number
- NCT02595372
- Locations
- 🇺🇸
Indiana University Health North Hospital, Carmel, Indiana, United States
🇺🇸Indiana University Health Hospital, Indianapolis, Indiana, United States
🇺🇸Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Impact of OCT1 on Metformin Tolerance
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- NHS Tayside
- Target Recruit Count
- 61
- Registration Number
- NCT02586636
- Locations
- 🇬🇧
Ninewells Hospital, Dundee, Angus, United Kingdom
GERD and Anti-Reflux Therapy Between Able-bodied and SCI Individuals
- First Posted Date
- 2015-10-23
- Last Posted Date
- 2016-11-15
- Lead Sponsor
- James J. Peters Veterans Affairs Medical Center
- Target Recruit Count
- 110
- Registration Number
- NCT02584751
- Locations
- 🇺🇸
James J. Peters VA Medical Center, Bronx, New York, United States
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2015-09-22
- Target Recruit Count
- 4238504
- Registration Number
- NCT02555852
- Locations
- 🇨🇦
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 44
- Registration Number
- NCT02552537
- Locations
- 🇨🇭
University Hospital Zurich, Zurich, Switzerland
🇪🇸Hospital Clinico San Carlos, Madrid, Spain
Different Dose of Intravenous Omeprazole to Treat Bleeding Ulcer With Adherent Clot
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Far Eastern Memorial Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02536989
- Locations
- 🇨🇳
Far Eastern Memorial Hospital, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.